The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 3 study of first-line crizotinib vs pemetrexed−cisplatin/carboplatin (PCC) in East Asian patients (pts) with ALK+ advanced non-squamous non-small cell lung cancer (NSCLC).
 
Shun Lu
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb
Research Funding - Lilly
Travel, Accommodations, Expenses - Roche
 
Tony Mok
Employment - The Chinese University of Hong Kong
Leadership - Sanomics Limited
Stock and Other Ownership Interests - Sanomics Limited
Honoraria - ACEA Biosciences; Amgen; AstraZeneca; Aveo/Biodesix; Biomarin; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; GlaxoSmithKline; Janssen; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Prime Oncology; Roche/Genentech; SFJ Pharmaceuticals Group; Vertex
Consulting or Advisory Role - ACEA Biosciences; Amgen; AstraZeneca; Aveo/Biodesix; Biomarin; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; geneDecode; Janssen; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Roche/Genentech; SFJ Pharmaceuticals Group; Vertex
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; GlaxoSmithKline; Janssen; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Prime Oncology; Roche/Genentech
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); SFJ Pharmaceuticals Group (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Boehringer Ingelheim; Lilly; Merck Serono; Pfizer; Roche
 
You Lu
No Relationships to Disclose
 
Jianying Zhou
No Relationships to Disclose
 
Yuankai Shi
No Relationships to Disclose
 
Virote Sriuranpong
Research Funding - Pfizer
 
James C. M. Ho
Honoraria - AstraZeneca; Boehringer Ingelheim; Lilly; MSD; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; MSD; Pfizer; Roche
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Lilly; MSD; Pfizer; Roche
Research Funding - ARIAD; AstraZeneca; AVEO; MSD; Roche
 
Choo Khoon Ong
No Relationships to Disclose
 
Chun-Ming Tsai
Honoraria - AstraZeneca; Boehringer Ingelheim; Lilly; Pfizer; Roche
 
Chin-Hee Chung
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
Travel, Accommodations, Expenses - Pfizer
 
Keith D. Wilner
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
Research Funding - Pfizer
Patents, Royalties, Other Intellectual Property - Pfizer
Travel, Accommodations, Expenses - Pfizer
 
Yiyun Tang
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Elizabeth Masters
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Paulina Selaru
Employment - Pfizer
Stock and Other Ownership Interests - 3M; Colgate Palmolive; EnteroMedics; GE Healthcare; NxStage; Pfizer; Zoetis
 
Yi-Long Wu
Honoraria - AstraZeneca; Lilly; Pfizer; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Merck; Roche
Research Funding - Boehringer Ingelheim (Inst); Roche (Inst)